Pembrolizumab plus chemotherapy in persistent, recurrent, or metastatic cervical cancer: A KEYNOTE-826 subgroup analysis

Basit Öğe Kaydı
dc.contributor.authorBaron-Hay, Sally
dc.contributor.authorTewari, Krishnansu S.
dc.contributor.authorColombo, Nicoletta
dc.contributor.authorMonk, Bradley J.
dc.contributor.authorDubot, Coraline
dc.contributor.authorValeria Caceres, M.
dc.contributor.authorHasegawa, Kosei
dc.date.accessioned2025-05-10T19:27:57Z
dc.date.issued2022
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstract[No abstract available]
dc.identifier.endpage117
dc.identifier.issn1743-7555
dc.identifier.issn1743-7563
dc.identifier.scopusqualityQ3
dc.identifier.startpage117
dc.identifier.urihttps://hdl.handle.net/20.500.14730/7147
dc.identifier.volume18
dc.identifier.wosWOS:000871956500161
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofAsia-Pacific Journal of Clinical Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.titlePembrolizumab plus chemotherapy in persistent, recurrent, or metastatic cervical cancer: A KEYNOTE-826 subgroup analysis
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu